Universal active surveillance for small renal masses
A study presented at the Society of Urologic Oncology (SUO) [...]
New first-line immunotherapy plus TKI combinations for metastatic kidney cancer
Approval of axitinib plus pembrolizumab and axitinib plus avelumab in [...]
Prognostic implications of aquaporin 9 expression in kidney cancer
Water channel proteins, or aquaporins (AQPs) have been found in [...]
Real world use of pazopanib after immunotherapy for advanced kidney cancer
A study published in Clinical Genitourinary Cancer last month describes [...]
Panobinostat plus everolimus not effective in metastatic kidney cancer
A recent phase I clinical trial assessed the combination of [...]
Avelumab as a first- or second-line treatment for metastatic kidney cancer
A recent study looked at the efficacy and safety of [...]
Comparison of first-line immunotherapy combinations for advanced kidney cancer
In this paper, three clinical trials with immunotherapy combinations for [...]
Lenvatinib plus pembrolizumab combination shows promise in metastatic kidney cancer
Interim results from an ongoing clinical trial of lenvatinib and [...]
Sunitinib and pazopanib for non-clear cell and sarcomatoid kidney cancer
Non-clear cell renal cell carcinoma (RCC) and sarcomatoid renal cell [...]
Negative effect on survival of kidney cancer patients of immediate sunitinib dose interruption
A recent study looked at the impact of stopping sunitinib [...]
